In the dynamic field of cancer research, the hunt for breakthroughs in early disease detection is critical for improving patient outcomes. Exosomes are garnering attention for their potential in cancer diagnostics. The emergence of exosomes and their cargo as important biomarkers in disease monitoring, early discovery, and precision medicine may herald a transformative era in patient care.

Extracellular vesicles (EVs) are tiny bubbles released by cells containing proteins and genetic material, offering insights into cell health and potential for disease detection. Scientists are exploring ways to customize EVs to deliver therapeutic agents to specific sites, potentially revolutionizing treatment for conditions like cancer and spinal cord injuries.

This interview discusses Biological Dynamics, its technology, and it’s future directions.

Biological Dynamics Is Transforming Exosome Research and Advancing Liquid Biopsy with Its Proprietary ExoVerita Pro Platform

Biological Dynamics, a privately held San Diego-based company, is poised to revolutionize exosome/extracellular vesicle (EV) isolation and enrichment by addressing current research challenges and ultimately driving new liquid biopsy advancements. Biological Dynamics has developed an automated bench-top device, ExoVerita Pro, that uses alternating current electrokinetics (ACE) (see details below) to separate exosomes/EVs from other material in small samples of plasma (50-250 µL). The platform offers a simple and automated workflow to enrich exosomes and EVs, bypassing many fundamental limitations of current isolation technologies. This technology is superior to the current exosome/EV separation methods such as ultracentrifugation and column purification in terms of purity and reproducibility and in process time, reducing it from days to hours. 

Unleashing the Power of Exosomes for Early Disease Detection

In today’s symptom-driven healthcare system, early stage disease can be difficult to diagnose as symptoms often do not appear until the disease has progressed, limiting treatment options. Additionally, there is a lack of effective diagnostic tools that can identify diseases in their nascent stages.

Unveiling the Journey Behind a Breakthrough in Early Detection of Pancreatic Cancer

New paper demonstrates effectiveness of exosome isolation technology in detecting Stage I and II pancreatic ductal adenocarcinoma (PDAC)

Member Spotlight: Biological Dynamics

Acclaimed Physician and Researcher Dr. Paul R. Billings Says Biological Dynamics’ Exosome Isolation Technology May Be the Key to Early Disease Detection and Other Diagnostic Applications

Efficacy of Liquid Biopsies Using Extracellular Vesicles for Patients with PDAC

In this interview Dr. Harmeet Dhani, MD, MSc, of Biological Dynamics, highlights his recent publication in Communications Medicine on the benefits of liquid biopsies and why the study investigated the potential of extracellular vesicles protein biomarkers as a detection method for pancreatic cancer. Dr. Dhani also discusses how the study incorporated machine learning and what information was used in the algorithm to help detect PDAC.

Biological Dynamics Partners With Pancreatic Cancer Consortium On Early Detection Study

Biological Dynamics said this week that it has partnered with the Pancreatic Cancer Early Detection (PRECEDE) Consortium for a validation study of its ExoVita pancreas assay, an exosome-derived blood-based test utilizing the firm's Verita platform.

Biological Dynamics and The Pancreatic Cancer Early Detection Consortium (PRECEDE) Collaborate to Improve Surveillance of Early Pancreatic Cancer

Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, and the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international, multi-institutional group of experts focused on increasing survival rates for pancreatic cancer patients, have signed a multi-year agreement to partner on patient surveillance for early-stage pancreatic cancer using Biological Dynamics’ ExoVita Pancreas Assay, powered by the Verita platform.

In this podcast Dr. Billings discusses:

• Personalized medicine.

• Biological Dynamics Overview: 10-year-old company, isolates plasma particles from minimal blood samples for diagnostics.

• Aiming for early-stage detection of pancreatic cancer to improve survival rates.

• Biological Dynamics unique approach to target exosomes instead of DNA/RNA for richer data; aims to replace invasive tests.

• Expanding technology to other cancers and potentially Alzheimer’s; involved in clinical trials.

How AI and advanced diagnostics are revolutionizing early disease detection

Innovative technologies for early disease detection and ongoing surveillance of high-risk individuals are vital components of prevention and treatment strategies.

New Study Demonstrates Efficient Exosome Isolation from Biological Fluids Using Proprietary Technology from Biological Dynamics

Biological Dynamics, a leader in exosome-isolation technology for early disease detection, announced a newly published study in the journal Electrophoresis titled, “Enhancement of Dielectrophoresis-Based Particle Collection from High Conducting Fluids Due to Partial Electrode Insulation.” The collaborative research with Oregon Health & Science University (OHSU) sheds light on the phenomenon occurring on Biological Dynamics’ ExoVerita platform that allows for the capture of biomarkers carried by nanoscale particles.

Biological Dynamics to Present Data at AACR Highlighting ExoVerita Platform-Enabled Earlier Detection of Pancreatic and Lung Cancers

Biological Dynamics, a life sciences company focused on developing and commercializing exosome isolation technology for earlier disease detection, will present data showing how the company’s ExoVerita™ platform can be utilized for early detection of lung and pancreatic cancers at the American Association of Cancer Research (AACR) annual meeting in Orlando, Fl., April 14-19. A case study of early pancreatic cancer management will also be discussed at the meeting. Biological Dynamics’ will exhibit its technology and early cancer detection assays at booth #1368.

Biological Dynamics: Zach Miller

Biological Dynamics, a San Diego-based company developing exosome-based cancer early detection tests, has appointed Zach Miller to its board of directors. Miller is the founder and managing partner of Parian Global Management. He also previously worked on finance teams a Slate Path Capital and Bain Capital, where he focused on medical and information technology companies. He holds a bachelor's degree from Williams College and a master's degree in philosophy with distinction from Worcester College, Oxford University.

How to catch cancer before catching its symptoms. Exo-what?

This week's guest is Dr. Paul Billings, a board-certified internist, renowned researcher, and clinical geneticist. Dr. Billings and Dr. Juneja talk about new methods of early detection of cancer and dive into Dr. Billings's recent research endeavor on exosomes and how they function to identify potentially cancerous cells from a single blood draw, even before symptoms occur. This revolutionary technology aims to redefine cancer

Biological Dynamics, OHSU Partner to Validate Pancreatic Cancer Early Detection Test

Biological Dynamics said on Wednesday that it has partnered with Oregon Health & Science University to study its ExoVita Pancreas assay for pancreatic cancer early detection.

San Diego company’s test to detect pancreatic cancer in early stages moves to human trials

Biological Dynamics spent more than a decade validating cancer diagnostic process spun out of UC San Diego and now has launched a study for people at high risk of pancreatic cancer.

Biological Dynamics’ Clinical Study Gets IRB Approval